Actualités 10163
Images about 10163
NEUROCRINE BIOSCIENCES, INC. : RBC Capital Markets conserve son opinion neutre
Tue, 11 Mar 2025 03:40:00 GMT
La recherche de chez RBC Capital Markets confirme son conseil et maintient son opinion neutre sur le dossier. L'objectif de cours est abaissé de 148 à 139 USD.
Neurocrine Biosciences, Inc. Presents at Leerink?s Global Healthcare Conference 2025, Mar-11-2025 11:20 AM
Tue, 11 Mar 2025 07:20:00 GMT
Okay. All right. We're ready to go. For our next session, we have Neurocrine Biosciences, and we're lucky enough to have Matt Abernethy, who's the CFO; and Todd ...